

# Nicola Lehners

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6996221/nicola-lehners-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40  
papers

539  
citations

13  
h-index

23  
g-index

41  
ext. papers

748  
ext. citations

3.8  
avg, IF

3.41  
L-index

#	Paper	IF	Citations
40	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , <b>2018</b> , 97, 197-207	3	104
39	Long-Term Shedding of Influenza Virus, Parainfluenza Virus, Respiratory Syncytial Virus and Nosocomial Epidemiology in Patients with Hematological Disorders. <i>PLoS ONE</i> , <b>2016</b> , 11, e0148258	3.7	62
38	Spectrum and functional validation of PSMB5 mutations in multiple myeloma. <i>Leukemia</i> , <b>2019</b> , 33, 447-456	5.7	51
37	Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. <i>European Journal of Cancer</i> , <b>2016</b> , 67, 200-212	7.5	50
36	Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. <i>Blood</i> , <b>2016</b> , 127, 2155-7	2.2	41
35	Isavuconazole shortens the QTc interval. <i>Mycoses</i> , <b>2018</b> , 61, 256-260	5.2	36
34	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <i>Leukemia</i> , <b>2020</b> , 34, 1853-1865	10.7	26
33	Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. <i>Cancer Medicine</i> , <b>2018</b> , 7, 307-316	4.8	21
32	HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 367-378	6.1	21
31	IKZF1/3 and CRL4 E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. <i>Haematologica</i> , <b>2020</b> , 105, e237-e241	6.6	20
30	Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3143-3152	2.2	20
29	2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 154-160	7.5	18
28	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>European Journal of Cancer</i> , <b>2020</b> , 140, 86-104	7.5	14
27	HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14527-e14527	2.2	12
26	Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial. <i>Blood</i> , <b>2020</b> , 136, 44-45	2.2	11
25	Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. <i>Nature Communications</i> , <b>2021</b> , 12, 6960	17.4	9
24	B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2029-2041	7.5	4

23	Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4349-4349	2.2	4
22	The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1501-1507	3	3
21	Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2660-2669	1.9	2
20	Cellular Immune Response after Vaccination in Patients with Cancer-Review on Past and Present Experiences.. <i>Vaccines</i> , <b>2022</b> , 10,	5.3	2
19	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
18	Characterization of Patients with Multiple Myeloma in Long- Term Remission. <i>Blood</i> , <b>2018</b> , 132, 4508-4508		1
17	Profiling of Oncogenic Signaling in Multiple Myeloma Association with Biology, Disease Progression and Prognosis. <i>Blood</i> , <b>2018</b> , 132, 3206-3206	2.2	1
16	Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 1-1	2.2	1
15	The Chromosomal Abnormalities Del(17p), t(4;14), and +1q21 Predict Progression From Smoldering to Symptomatic Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 1806-1806	2.2	1
14	ATG and Statins Reduce Incidence of Severe Chronic Gvhd By Distinct Mechanisms Involving CXCL9 and Kynurenine Catabolism. <i>Blood</i> , <b>2015</b> , 126, 856-856	2.2	1
13	Parainfluenza Virus Infections in Patients with Hematologic Malignancies or Following Stem Cell Transplantation: Analysis of Clinical Characteristics, Nosocomial Transmission and Prolonged Viral Shedding. <i>Blood</i> , <b>2016</b> , 128, 3401-3401	2.2	1
12	Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 14-14	2.2	
11	Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. <i>Blood</i> , <b>2021</b> , 138, 3792-3792	2.2	
10	Prognostic Impact of Gastrointestinal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 5400-5400	2.2	
9	Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma. <i>Blood</i> , <b>2019</b> , 134, 1783-1783	2.2	
8	Analysis of Prognostic Factors and Outcome of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract. <i>Blood</i> , <b>2015</b> , 126, 3964-3964	2.2	
7	Analysis of Long-Term Survival in Multiple Myeloma Patients after First-Line Autologous Stem Cell Transplantation: Impact of Clinical Risk Factors and Duration of Response. <i>Blood</i> , <b>2016</b> , 128, 4649-4649	2.2	
6	Oncogene Induced Senescence As a Potential Breakpoint Mechanism Against Malignant Transformation in Plasma Cell Disorders. <i>Blood</i> , <b>2016</b> , 128, 4474-4474	2.2	

- 5 Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.. *Blood*, **2012**, 120, 3086-3086 2.2
- 4 Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. *Blood*, **2012**, 120, 4600-4600 2.2
- 3 Outbreak of Nosocomial Respiratory Syncytial Virus Infections in a Hematology and Transplant Unit.. *Blood*, **2012**, 120, 3032-3032 2.2
- 2 BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. *Blood*, **2012**, 120, 4040-4040 2.2
- 1 Analysis of Prognostic Factors in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma and Skeletal Involvement: A Novel Simple Prognostic Score Identifies a Large Group of Low Risk Patients with an Excellent Prognosis. *Blood*, **2012**, 120, 1590-1590 2.2